The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that
1) a candidate biomarker has already been identified,
2) assay technology has already been developed, and
3) a working hypothesis regarding context of use is in place
Also listed under U44
The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies.
Also listed under R21.
The goal of this initiative is to support the identification, validation and manipulation of neural circuits that underlie cognitive, emotional, and social processes impacted in mental illnesses including alcohol use disorder and other substance abuse. The initiative is focused on probing circuit mechanisms underlying neuro-psychiatrically relevant behavior through studies in non-human primates. This initiative is intended to complement existing institute-funded preclinical investigation of circuits which have often focused on smaller brains.
The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
This funding opportunity aims to stimulate multi-disciplinary collaboration and secondary analyses of existing clinical research datasets, from two or more multi-site clinical research studies, for addressing scientific and / or clinically relevant hypotheses that have the potential to address knowledge gaps to inform future clinical trials and/or improve clinical care in research areas within the NINDS mission. For purposes of this RFA, "existing clinical research datasets" refers to datasets from clinical trials, natural history studies, and / or comparative effectiveness research studies but excludes "mechanistic clinical studies" and "basic experimental studies of humans" (for definitions see https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-011.html and https://grants.nih.gov/grants/glossary.htm#BasicExperimentalStudieswithHumans, respectively). This RFA will support the curation and analyses of datasets from two or more multi-site clinical research studies to conduct additional secondary analyses; it will not support the collection of new data.
The purpose of this Funding Opportunity Announcement [FOA] is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.
Genome-wide association studies (GWAS) have identified statistical relationships between tens of thousands of common single nucleotide variants and over a thousand traits. Due to the correlated nature of nearby genetic variants, GWAS implicate regions of the genome and do not necessarily pinpoint the causal variant(s), gene(s) or mechanism(s) underlying the trait association. The purpose of this funding opportunity announcement is to support systematic fine-mapping of genome-wide significant risk loci associated with serious mental illnesses through robust statistical genetic and functional genomic approaches.
The Ray Charles Foundation Scholars Fund in Neurosurgery provides a unique opportunity for one individual to spend a full year at the world-class Cedars-Sinai Medical Center in Los Angeles, gaining valuable hands-on experience in neurosciences and learning directly from a team of neuroscience innovators at one of our research laboratories.
This program aims to promote and enhance diversity in neurosciences by emphasizing student participation from Historically Black Colleges and Universities (HBCU). Available areas of research include nanomedicine, Alzheimer's disease diagnosis and treatment, tumor immunology, blood-brain barrier and drug delivery, and gene therapy and discovery.
Open to undergraduate, graduate, MD and PhD students with an interest in neuroscience
The Agency for Toxic Substances and Disease Registry (ATSDR) is soliciting investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the ATSDR National ALS Registry's mission. The National ALS Registry's goals are to estimate the number of new ALS cases each year, estimate the number of people who have ALS at a specific point in time, better understand who gets ALS, and identify what contributing factors, including environmental, may affect ALS. ATSDR is seeking investigator-initiated research that will identify and evaluate risk factors contributing to ALS, with preferred focus in this Notice of Funding Opportunity on factors related to military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents.
This Funding Opportunity Announcement (FOA) invites applications to conduct new research on automobile technology for signaling early signs of cognitive impairment in older drivers.
Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.
The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.
This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA-supported Alzheimer's Disease Research Centers (ADRCs). An additional activity will be to define appropriate imaging protocols, as well as assess and anticipate advances in neuroimaging technologies and techniques for inclusion in the standardized protocols to maximize utility for the field of Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) research.
This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.
This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.
This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multi-disciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in individuals with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.
This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including Fundamental brain function relevant to substance use.
This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).
This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.